Subscribe
formatoriginal-regeneron
Formatoriginal / Shutterstock.com
28 October 2021Alex Baldwin

Regeneron convinces PTAB to review Novartis syringe patent

The  US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant  Regeneron.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.


Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

More on this story

Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

More features

UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC
‘This is not a rescue deal’: How an acquisition fits London firm's plan
Alston & Bird partner with strong Japanese ties jumps to new firm